000			04129nam a22004337a 4500
008			240723s20242024 xxu||||| |||| 00| 0 eng d
022			_a1043-3074
040			_aOvid MEDLINE(R)
099			_a38433326
245			_aThe impact of COVID-19 and vaccination status on outcomes in veterans with head and neck squamous cell carcinoma.
251			_aHead & Neck. 2024 Mar 03
252			_aHead Neck. 2024 Mar 03
253			_aHead & neck
260			_c2024
260			_p2024 Mar 03
265			_saheadofprint
265			_tPublisher
266			_d2024-07-23
501			_aAvailable online from MWHC library: 1996 - present
520			_aBACKGROUND: The impact of both COVID-19 infection and vaccination status on patients with head and neck squamous cell carcinoma (HNSCC) remains unknown.
520			_aCONCLUSION: COVID-19 infection may significantly increase rates of 60-day mortality and respiratory complications in patients with HNSCC. COVID-19 vaccination between 2 weeks and 6 months prior to infection may decrease severity of respiratory complications but did not show significant mortality benefits in this study. These data highlight the need for surveillance of respiratory infection and vaccination in this vulnerable population. Copyright © 2024 Wiley Periodicals LLC.
520			_aMETHODS: This was a retrospective cohort study through the Veterans Affairs (VA) Corporate Data Warehouse of Veterans with HNSCC who were tested for COVID-19 during any inpatient VA medical center admission. A cohort of patients was created of Veterans with a diagnosis of HNSCC of the oral cavity,oropharynx, hypopharynx, larynx, and nasopharynx based on International Classification of Disease (ICD) codes. Data collected included clinical/demographic data, vaccination status, and incidence of 60-day mortality, 60-day cardiovascular complication (including myocardial infarction, venous thromboembolism, cerebrovascular accident), and 60-day respiratory complication (including acute respiratory failure, acute respiratory distress syndrome, and pneumonia). The interactions between COVID-19 infection, vaccination status, morbidity and mortality were investigated.
520			_aOBJECTIVE: To determine the impact of COVID-19 infection and vaccination status on 60-day mortality, cardiovascular, and respiratory complications in patients with a prior diagnosis of HNSCC.
520			_aRESULTS: Of the 14 262 patients with HNSCC who were tested for COVID-19 during inpatient admission, 4754 tested positive (33.3%), and 9508 (67.7%) tested negative. Patients who tested positive demonstrated increased 60-day mortality (4.7% vs. 2.0%, respectively; p < 0.001), acute respiratory failure (ARF; 15.4% vs. 7.1%, p < 0.001), acute respiratory distress syndrome (ARDS; 0.9% vs. 0.2%, p < 0.001), and pneumonia (PNA; 20.0% vs. 6.4%, p < 0.001) compared to those who never tested positive, respectively. Patients who received COVID-19 vaccination between 2 weeks and 6 months prior to a positive test demonstrated decreased rates of ARF (13.2% vs. 16.0%, p = 0.034) and PNA (16.7% vs. 20.9%, p = 0.003) compared to the unvaccinated group. A logistic regression of patients with COVID-19 infections who died within 60 days was performed, with no significant survival advantage among patients vaccinated between 2 weeks and 6 months prior to the positive test.
546			_aEnglish
650			_zAutomated
650			_aIN PROCESS -- NOT YET INDEXED
651			_aMedStar Health Research Institute
656			_aMedStar Georgetown University Hospital/MedStar Washington Hospital Center
656			_aOtolaryngology Residency
657			_aJournal Article
700			_aChisolm, Paul _bMGUH _cOtolaryngology Residency _dMD
700			_aChou, JiLing _bMHRI
700			_aJohns, James _bMGUH _cOtolaryngology Residency _dMD
700			_aRandolph, Jackson _bMGUH _cOtolaryngology Residency _dMD
790			_aJohns JD, Choe EJ, Chisolm PF, Pothast MJ, Randolph JR, Chou J, Maxwell JH
856			_uhttps://dx.doi.org/10.1002/hed.27714 _zhttps://dx.doi.org/10.1002/hed.27714
942			_cART _dArticle
999			_c14225 _d14225